Imlygic Interactions
There are 276 drugs known to interact with Imlygic (talimogene laherparepvec), along with 4 disease interactions. Of the total drug interactions, 270 are major, and 6 are moderate.
- View all 276 medications that may interact with Imlygic
- View Imlygic disease interactions (4)
Most frequently checked interactions
View interaction reports for Imlygic (talimogene laherparepvec) and the medicines listed below.
- Actemra (tocilizumab)
- Adriamycin (doxorubicin)
- Amicar (aminocaproic acid)
- Aricept (donepezil)
- atorvastatin
- Avastin (bevacizumab)
- Banzel (rufinamide)
- Baraclude (entecavir)
- bleomycin
- Blincyto (blinatumomab)
- chloramphenicol
- Clozaril (clozapine)
- Corlanor (ivabradine)
- Coumadin (warfarin)
- Cresemba (isavuconazonium)
- cyclophosphamide
- Cymbalta (duloxetine)
- Diflucan (fluconazole)
- Epidiolex (cannabidiol)
- Farydak (panobinostat)
- Genvoya (cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide)
- Imbruvica (ibrutinib)
- Imuran (azathioprine)
- Isentress (raltegravir)
- Jadenu Sprinkle (deferasirox)
- Kalydeco (ivacaftor)
- Keytruda (pembrolizumab)
- Lamictal (lamotrigine)
- midazolam
- Stribild (cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil)
Imlygic disease interactions
There are 4 disease interactions with Imlygic (talimogene laherparepvec) which include:
More about Imlygic (talimogene laherparepvec)
- Imlygic consumer information
- Compare alternatives
- Pricing & coupons
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.